Lovaza® and Microvascular Function in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
HypertriglyceridemiaDiabetic Neuropathy
Interventions
DRUG

omega-3-ethyl esters

Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (\>500 mg/dL) triglyceride (TG) levels in adult patients.

DRUG

Placebo

Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.

Trial Locations (1)

23510

Strelitz Diabetes Center, Norfolk

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Eastern Virginia Medical School

OTHER

NCT00931879 - Lovaza® and Microvascular Function in Type 2 Diabetes | Biotech Hunter | Biotech Hunter